ROYALTY PHARMA PLC- CL A (RPRX)       41.865  +1.68 (+4.17%)

41.865  +1.68 (+4.17%)

GB00BMVP7Y09 - Common Stock

ROYALTY PHARMA PLC- CL A41.865

NASDAQ:RPRX (10/4/2022, 11:37:54 AM)+1.68 (+4.17%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/bmo Earnings (Next) 11-08 2022-11-08
Ins Owners 0.13% Inst Owners 67.17%
Market Cap 18.22B Shares 435.32M
PE 17.74 Fwd PE 11.62
Dividend Yield 1.88% Analysts 81.11
IPO 06-16 2020-06-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RPRX Daily chart

Company Profile

Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 66 full-time employees. The company went IPO on 2020-06-16. The firm collaborate with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products and 10 development-stage product candidates. Those products include AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta. The development-stage product candidates include Aficamten, BCX9930, CPI-0209, Gantenerumab, Omecamtiv mecarbil, Otilimab, Pelabresib, PT027, Seltorexant and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments, and Royalty Pharma Collection Trust, among others.

Company Info

ROYALTY PHARMA PLC- CL A

110 East 59Th Street

New York City NEW YORK 10022

P: 12128830200.0

CEO: Pablo Legorreta

Employees: 66

Website: https://www.royaltypharma.com

RPRX News

News Imagea month ago - Royalty Pharma plcRoyalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming...

News Image2 months ago - Market News VideoRoyalty Pharma Larger Than S&P 500 Component Molina HealthcareNews Image2 months ago - Theravance Biopharma, Inc.Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine...

News Image2 months ago - Royalty Pharma plcRoyalty Pharma Reports Second Quarter 2022 Results

Strong growth in net cash provided by operating activities and Adjusted Cash Receipts(1)Announced transactions of up to $2.5 billion year-to-date,...

News Image2 months ago - Blueprint Medicines CorporationBlueprint Medicines Reports Second Quarter 2022 Results

-- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue...

News Image3 months ago - Market News VideoFirst Week of RPRX September 16th Options Trading

RPRX Twits

Here you can normally see the latest stock twits on RPRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example